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B cell responses are regulated by antigen acquisi-
tion, processing, and presentation to helper T cells.
These functions are thought to depend on contractile
activity of non-musclemyosin IIa. Here, we show that
B cell-specific deletion of the myosin IIa heavy chain
reduced the numbers of bone marrow B cell precur-
sors and splenic marginal zone, peritoneal B1b, and
germinal center B cells. In addition, myosin IIa-defi-
cient follicular B cells acquired an activated pheno-
type and were less efficient in chemokinesis and
extraction of membrane-presented antigens. More-
over, myosin IIa was indispensable for cytokinesis.
Consequently, mice with myosin IIa-deficient B cells
harbored reduced serum immunoglobulin levels and
did not mount robust antibody responses when
immunized. Altogether, these data indicate that
myosin IIa is a negative regulator of B cell activation
but a positive regulator of antigen acquisition from
antigen-presenting cells and thatmyosin IIa is essen-
tial for B cell development, proliferation, and anti-
body responses.
INTRODUCTION
B cell activation is initiated when B cells bind antigen via their
cell-surface B cell antigen receptors (BCRs). This induces
signaling and internalization of BCR-antigen complexes. Subse-
quently, antigen is trafficked along the endosomal pathway, pro-
cessed into peptides, and loaded on major histocompatibility
complex class II (MHC class II) molecules for presentation to
T cells. Cognate interaction with T cells results in full activation
and proliferation of the B cell and differentiation into high-affinity
antibody-secreting cells. Some B cells, e.g., marginal zone (MZ)
B cells, mostly encounter small soluble antigens. However, many
B cells engage antigen bound to antigen-presenting cells
(APCs), such as subcapsular macrophages and follicular den-
dritic cells (FDCs), which display unprocessed antigen bound2342 Cell Reports 23, 2342–2353, May 22, 2018 ª 2018 The Author(s
This is an open access article under the CC BY license (http://creativeto complement or Fc receptors on their cell surfaces (Carrasco
and Batista, 2007; Gonzalez et al., 2010; Junt et al., 2007;
Phan et al., 2007; Qi et al., 2006). In contrast to acquisition of
free-floating soluble antigen, capture of membrane-bound anti-
gens from APCs requires B cells to apply force to overcome
the membrane tether. It has been hypothesized that non-muscle
myosin IIa generates these forces.
Myosin IIa is a motor protein from the class II family of
myosin proteins, which have been implicated in generation
of cortical tension (Murrell et al., 2015), separation of the
mitotic spindle (Rosenblatt et al., 2004), formation of the cleav-
age furrow during cytokinesis (Straight et al., 2003), and
cellular locomotion (Kolega, 1998). Myosin IIa is the only class
II myosin expressed in lymphocytes. In T cells, it regulates
maturation of immune synapses (Kumari et al., 2012), de-
adhesion from intercellular adhesion molecule-1 (ICAM-1)
(Morin et al., 2008), and interstitial migration and lymph node
retention (Jacobelli et al., 2010). In vitro studies using primary
B cells or B cell lines treated with blebbistatin, an inhibitor of
class II myosin proteins, revealed a role for myosin IIa in
B cell antigen extraction from membrane substrates (Natkan-
ski et al., 2013) and antigen presentation to T cells (Vascotto
et al., 2007). However, the role of myosin IIa in B cell functions
in vivo has not been investigated.
Here, using mice in which myosin IIa was conditionally or
inducibly deleted from B cells, we show that myosin IIa is
required for B cell development at the pro-B cell stage. More-
over, when we deleted myosin IIa in more mature B cells,
development and maintenance of splenic MZ, peritoneal B1b,
and steady-state germinal center (GC) B cells was disturbed.
Myosin IIa-deficient follicular B cells developed normally; how-
ever, these cells acquired an activated phenotype. Culturing
myosin IIa-deficient B cells in the presence of various activating
stimuli revealed a defect in cytokinesis. In addition, myosin IIa-
deficient B cells showed impaired migration and were less effi-
cient in internalizing membrane-tethered antigen, whereas
internalization of soluble antigen was unperturbed. We also
observed reduced acquisition of antigen from FDCs in vivo.
Collectively, these defects resulted in reduced steady-state
serum antibody levels and diminished antibody responses
in vivo.).
commons.org/licenses/by/4.0/).
Figure 1. Disturbed B Cell Development and
Maintenance after B Cell-Specific Deletion
of Myosin IIa
(A) Flow cytometric analysis of B220+CD19+ cells in
the bone marrow (BM) of Mb1Cre+Myh9wt/fl and
Mb1Cre+Myh9fl/fl mice.
(B) Quantification of precursor B cell subsets in the
BM of Mb1Cre+Myh9wt/wt (n = 3), Mb1Cre+Myh9wt/fl
(n = 4), Mb1Cre+Myh9fl/fl (n = 4), and Cre-negative
littermates (n = 4).
(C) Flow cytometric analysis of B220+AA4.1 cells in
spleens of Mb1Cre+Myh9wt/fl and Mb1Cre+Myh9fl/fl
mice.
(D) Quantification of B cell subsets in spleens of
Mb1Cre+Myh9wt/wt (n = 3), Mb1Cre+Myh9wt/fl (n = 4),
Mb1Cre+Myh9fl/fl (n = 4), and Cre-negative litter-
mates (n = 4).
(E) Flow cytometric analysis of B220+AA4.1 cells
in spleens of CD23Cre+Myh9wt/fl and CD23Cre+
Myh9fl/fl mice.
(F) Quantification of B cell subsets in spleens of
CD23Cre+Myh9wt/fl (n = 6) and CD23Cre+Myh9fl/fl
(n = 4) mice.
(G) Flow cytometric analysis of B220+ cells in the
peritoneal cavity of CD23Cre+Myh9wt/fl and
CD23Cre+Myh9fl/fl mice.
(H) Quantification of B cell subsets in the peritoneal
cavity of CD23Cre+Myh9wt/fl (n = 6) and CD23Cre+
Myh9fl/fl (n = 4) mice.
(I) Quantification of B cell subsets 14 days after the
start of tamoxifen treatment in spleens of
R26ERT2Cre+Myh9wt/wt, R26ERT2Cre+Myh9wt/fl,
R26ERT2Cre+Myh9fl/fl, and Cre-negative mixed BM
chimeras (n = 5).
(J) Quantification of MZ B cell numbers in spleens of
R26ERT2Cre+Myh9wt/fl and R26ERT2Cre+Myh9fl/fl
mice over time since the start of tamoxifen
treatment.
Plotted are means ± SD per mouse. *p < 0.05,
**p < 0.01, ***p < 0.001 (unpaired t test). Trans,
transitional B cells; MZ, marginal zone B cells; Fo,
follicular B cells; GC, B220+Fas+CD38 germinal
center B cells. See also Figures S1 and S2.RESULTS
Myosin IIa Is Required for Bone Marrow B Cell
Development
Germline knockout of Myh9, encoding the myosin IIa heavy
chain, leads to embryonic death (Conti et al., 2004). To study
the role of myosin IIa in B cells, we crossed Myh9fl/fl mice, in
which exon 3 of Myh9 is flanked by LoxP sites (Jacobelli et al.,
2010), with Cd79aCre (Mb1Cre) and Fcer2Cre (CD23Cre) mice,
resulting in mice in which Myh9 is conditionally deleted from
early bone marrow (BM) B cell precursors and more mature
splenic transitional B cells, respectively (Hobeika et al., 2006;
Kwon et al., 2008). Flow cytometric analysis of the BM and pe-
ripheral lymphoid organs of Mb1Cre+Myh9fl/fl mice revealedCellseverely reduced numbers of pro-B cells
and in all subsequent stages of B cell
development compared to Mb1Cre+
Myh9wt/fl, Mb1Cre+Myh9wt/wt, or Cre-negative littermates (Figures 1A–1D), demonstrating that B cell
development is blocked immediately after first expression of
Cd79a. No differences were found in B cell development or
mature B cell numbers between haploinsufficient and myosin
IIa-wild-type mice, suggesting that a partial reduction of myosin
IIa levels does not impair B cell development or maintenance of
mature B cells. We conclude that myosin IIa is essential for early
steps of B cell development.
Myosin IIa Regulates Development and Maintenance of
Splenic MZ and Peritoneal B1b B Cells
To investigate the role of myosin IIa in mature B cells, we
analyzed CD23Cre+Myh9fl/fl mice and found that total mature
B cell numbers in the spleen, BM, and lymph nodes (LNs) wereReports 23, 2342–2353, May 22, 2018 2343
Figure 2. Myosin IIa-Deficient Follicular B
Cells Express Altered Levels of Surface Acti-
vation Markers
(A) Surface expression of CD23, IgM, andMHC class
II on follicular B cells of CD23Cre+Myh9wt/fl and
CD23Cre+Myh9fl/fl mice.
(B) Relative expression of surface CD23, IgM, and
MHC class II on follicular B cells of R26ERT2Cre+-
Myh9wt/fl and R26ERT2Cre+Myh9fl/fl mice 18 days
after the start of tamoxifen treatment.
Each dot represents one mouse. Horizontal bars
reflect mean ± SD. Data are normalized on expres-
sion levels of Cre+Myh9wt/fl littermate follicular B
cells. **p < 0.01, ***p < 0.001 (unpaired t test). See
also Figure S3.normal (Figures 1E, 1F, S1A, and S1B). However, splenicMZ and
steady-state GC B cell numbers were reduced (Figures 1E
and 1F). In the peritoneal cavity, the numbers of B1b B cells
were also reduced, whereas B1a and B2 numbers were similar
as in control mice (Figures 1G and 1H). Deletion of myosin IIa
in follicular B cells was confirmed by analyzingmRNA expression
of Myh9 exon 3 and myosin IIa protein expression by western
blot (Figures S2A and S2B). In addition, reduced myosin IIa pro-
tein levels were detected by flow cytometry in splenic CD23-ex-
pressing T2 cell and follicular B cell subsets of CD23Cre+Myh9fl/fl
mice, whereas CD23-negative T1 cells expressed normal levels
(Figure S2C). In the peritoneal cavity, we observed reduced
myosin IIa protein levels in B1b and B2 cells. However, B1a
B cells retained myosin IIa expression (Figure S2D), most likely
because these cells derive from fetal liver cells that do not ex-
press CD23.
The loss of MZB cells was B cell intrinsic, because it was reca-
pitulated when BM of CD23Cre+Myh9fl/fl was mixed with 4 vol-
umes of CD45.1 BM and transferred into sub-lethally irradiated
Rag1-knockout (KO) mice (Figure S1C). Competition with wild-
type B cells also reduced the numbers of myosin IIa-deficient
follicular B cells, although not as severely as the number of MZ
B cells.
Splenic MZ and peritoneal B1 B cells may share develop-
mental and maintenance cues (Niiro and Clark, 2002). To inves-
tigate whether myosin IIa plays a role in the development or
maintenance of MZ B cells, we mixed BM cells from
R26ERT2Cre+Myh9fl/fl and muMT mice and transferred them
into sub-lethally irradiated Rag1-KO mice. In the resulting
mice, myosin IIa can be acutely deleted specifically in B cells
by administration of tamoxifen. Reduced levels of myosin IIa pro-2344 Cell Reports 23, 2342–2353, May 22, 2018tein were detected in peripheral blood
B cells by day 8 after the start of tamoxifen
treatment, with maximally reduced levels
from day 14 onward (Figure S2E). On day
14 after starting tamoxifen administration,
MZ B cell numbers were not significantly
different among R26ERT2Cre+Myh9wt/wt,
R26ERT2Cre+Myh9wt/fl, and R26ERT2Cre+
Myh9fl/fl chimeras (Figure 1I). However,
R26ERT2Cre+Myh9fl/fl MZ B cell numbers
started to decline 18 days after the startof tamoxifen treatment (Figure 1J). In contrast, steady-state
R26ERT2Cre+Myh9fl/fl GC B cell numbers were already reduced
at day 14 (Figure 1I), indicating that myosin IIa is required for
acute maintenance of GC B cells, but not MZ B cells. However,
myosin IIa is important for MZ B cell development and long-term
maintenance.
Development and maintenance of MZ B cells requires correct
localization to the MZ (Lu and Cyster, 2002). To investigate local-
ization of myosin IIa-deficient MZ B cells, we intravenously (i.v.)
injected R26ERT2Cre+Myh9fl/fl BM chimeras with an anti-
Cd19-phycoerythrin (PE) antibody to label cells exposed to
blood 14 days after the start of tamoxifen treatment. At this
time point, myosin IIa is deleted, but MZ B cell numbers have
not yet declined. Five minutes after injection of anti-Cd19-PE
antibody, mice were culled and binding of antibody was
analyzed by flow cytometry. Labeling of MZ B cells was slightly
increased in R26ERT2Cre+Myh9fl/fl chimeras (Figure S1D), indi-
cating that myosin IIa-deficient MZ B cells were localized to
the MZ or red pulp before their disappearance.
Myosin IIa-Deficient Follicular B Cells Display Elevated
Surface Activation Markers
Although follicular B cells in CD23Cre+Myh9fl/fl mice developed
in normal numbers, they expressed higher levels of surface
Fcer2 (CD23) and MHC class II and reduced levels of surface
immunoglobulin M (IgM) (Figure 2A), indicating an activated
phenotype. A similar follicular B cell surface marker phenotype
was induced by acute depletion of myosin IIa in R26ERT2Cre+
Myh9fl/fl mixed BM chimeras (Figure 2B), suggesting that myosin
IIa is continuously required to maintain a resting surface marker
phenotype of follicular B cells. The surface marker phenotype
was B cell intrinsic, because it was also observed in myosin IIa-
deficient follicular B cells of 20% CD23Cre+Myh9fl/fl, 80%
CD45.1 mixed BM chimeras (Figure S3A). However, we could
not detect significant changes in expression of other activation
markers, such as Cd44, Cd69, and Cd86 (Figure S3B). No differ-
ences were found in surface marker expression of B cells with
wild-type and haplosufficient myosin IIa levels (data not shown),
indicating that a partial reduction of myosin IIa levels has no ef-
fect on the surface marker phenotype.
To find clues of the signaling pathways that drive these pheno-
typic changes, we sorted follicular B cells of CD23Cre+Myh9wt/fl
and CD23Cre+Myh9fl/fl mice by flow cytometry and analyzed
gene expression by RNA sequencing. In myosin IIa-deficient
B cells, 8 genes were significantly upregulated and 32 genes
were significantly downregulated compared to haploinsufficient
B cells (Table S1). The downregulated genes included the puta-
tive p53 target genes Dusp1, Ets2, S100a9, and Zpf36l2, in line
with a report that myosin IIa post-transcriptionally stabilizes
p53 (Schramek et al., 2014). However, the RNA sequencing
(RNA-seq) data did not reveal clues as to what signaling path-
ways may be dysregulated in myosin IIa-deficient B cells.
MZ B cell development requires Adam10-mediated Notch2
cleavage and signaling (Gibb et al., 2010; Hammad et al.,
2017), an event that might depend on myosin IIa-mediated
forces or tension. To interrogate the role of myosin IIa in
Adam10 translocation to the plasma membrane, we stimulated
myosin IIa-deficient B cells with soluble anti-IgM and analyzed
Adam10 surface expression by flow cytometry. A similar in-
crease in Adam10 surface expression was detected in myosin
IIa-deficient and myosin IIa-proficient B cells (Figures S4A and
S4B). In agreement, myosin IIa-deficient B cells normally upre-
gulated the Notch2 target genes Deltex1, Hes1, and Hes5
when cultured on OP9 cells expressing the Notch ligand Dll1
(Figure S4C). We conclude that myosin IIa is not involved in
Notch2 signaling.
BCRSignaling and Internalization of Soluble AntigenAre
Normal in Myosin IIa-Deficient B Cells
A lack of MZ B cell development, upregulation of CD23 and
MHC class II, and decreased surface IgM expression have
been associated with increased BCR signaling (Goodnow
et al., 1988; Pillai and Cariappa, 2009). Thus, we hypothesized
that myosin IIa is a negative regulator of BCR signaling. To
study the role of myosin IIa in the regulation of BCR signaling,
we stimulated myosin IIa-proficient and myosin IIa-deficient B
cells with soluble anti-IgM and found that phosphorylation of
Syk, Blnk, and Akt and intracellular calcium fluxes were similar
(Figures S5A and S5B), suggesting proximal BCR signaling is
unaffected by myosin IIa-deletion. In addition, prolonged stim-
ulation of myosin IIa-deficient cells with soluble BCR ligands re-
sulted in normal upregulation of the activation markers Cd69,
Cd86, and MHC class II, albeit to slightly lower levels than in
CD23Cre+Myh9wt/fl cells (Figure S5C), suggesting myosin IIa
is also not involved in regulating more distal BCR signaling
pathways. Next, we analyzed internalization and processing
of soluble antigen using DNA-based antigen degradation sen-
sors as described previously (Nowosad et al., 2016). Myosin
IIa-deficient B cells were as efficient in internalizing solubleanti-immunoglobulin k (Igk) as myosin IIa-proficient cells (Fig-
ure S5D), in agreement with previous reports for B cells treated
with blebbistatin (Natkanski et al., 2013). Blebbistatin has also
been reported to reduce antigen presentation capability of pri-
mary B cells and B cell lymphoma cell lines (Vascotto et al.,
2007). However, similar levels of MHC class II-bound Ea pep-
tide were detected at the cell surface of CD23Cre+Myh9wt/fl
and CD23Cre+Myh9fl/fl B cells after stimulation with anti-Igk
and Ea peptide-loaded microbeads (Figure S5E). Altogether,
these findings indicate that myosin IIa is not required for the
regulation of BCR signaling or for internalization, processing,
and presentation of soluble antigen.
Myosin IIa-Deficient B Cells Are Less Efficient at
Extracting Antigen from Membrane Substrates
To investigate the role of myosin IIa in BCR signaling and inter-
nalization in response to membrane-presented antigen, we
made use of a large-scale imaging approach of primary B cells
on antigen-presenting plasma membrane sheets (PMSs) as
developed previously (Nowosad et al., 2016). PMSs are flexible
membrane substrates that facilitate B cell synapse formation,
BCR signaling, and antigen internalization when coated with an-
tigen. After 40min on anti-Igk-coated PMSs,myosin IIa-deficient
B cells showed significantly less, but not absent, antigen inter-
nalization compared to myosin IIa-proficient cells (Figure 3A),
showing that myosin IIa is important for efficient acquisition of
membrane-bound antigen. To investigate whether the reduced
internalization of membrane-bound antigen affects termination
of BCR signaling, phosphorylation of BCR signaling pathway
components was analyzed in myosin IIa-deficient B cells
engaging antigen on PMS. However, we did not observe signif-
icant changes in phosphorylation of Blnk, Syk, or Erk (Figures
3B and 3C). Thus, myosin IIa does not regulate BCR signaling
under these conditions.
Myosin IIa Is Required for Efficient Migration and In Vivo
Trafficking of B Cells
Adhesion to ICAM-1 lowers the threshold for B cell activation by
promoting synapse formation (Carrasco et al., 2004). To study
the adhesive properties of myosin IIa-deficient B cells, we stim-
ulated cells with anti-IgM in the presence of soluble ICAM-1 and
analyzed ICAM-1 binding to the cell surface by flow cytometry. In
both CD23Cre+Myh9fl/fl and CD23Cre+Myh9fl/wt B cells, binding
of ICAM-1was induced to a similar extent (Figure S6A). Adhesion
of anti-IgM or MnCl2-stimulated B cells to immobilized ICAM-1
was also similar between myosin IIa-deficient and myosin IIa-
proficient B cells (Figure S6B).
Using time-lapse imaging, we analyzed motility of myosin IIa-
deficient B cells on ICAM-1-coated glass in the presence of
Cxcl13 and observed reduced crawling speed compared to
CD23Cre+Myh9fl/wt B cells (Figure 4A; Video S1). A fraction of
myosin IIa-deficient cells developed elongated uropods
(Video S1). In Transwell assays, myosin IIa-deficient B cells dis-
played reduced migration toward Cxcl13, Cxcl12, and Ccl21
(Figure 4B). Coating of Transwell membranes with ICAM-1 facil-
itated robust migration of myosin IIa-proficient B cells, but not of
myosin IIa-deficient B cells. In contrast, coating of Transwell
membranes with anti-Igk, a stronger adhesive, severely reducedCell Reports 23, 2342–2353, May 22, 2018 2345
Figure 3. Myosin IIa-Deficient B Cells Are Less Efficient at Internalizing Membrane-Bound Antigen In Vitro
(A) Side view reconstructions and quantification of internalized antigen of follicular B cells (blue) fromCD23Cre+Myh9wt/fl and CD23Cre+Myh9fl/fl mice after 40min
of interaction with plasma membrane sheet (PMS)-bound antigen (red).
(B) Top view of synapse plane showing pBlnk staining (green) in follicular B cells (blue) from CD23Cre+Myh9wt/fl and CD23Cre+Myh9fl/fl mice after 15 min of
interaction with PMS-bound antigen (red).
(C) Quantification of synaptic pBlnk (left), pSyk (middle), and pErk (right) after 20, 20, and 15min of interaction with PMS, respectively. Cells that landed outside of
PMS were used as unstimulated controls.
Mean ± SEM (n > 192 cells). ***p < 0.001 (Mann-Whitney U test). Fu, fluorescence units. See also Figure S5.migration of CD23Cre+Myh9fl/wt and nearly abolished migration
of CD23Cre+Myh9fl/fl B cells. Altogether, these data indicate
that B cells require myosin IIa for detachment from adhesive
surfaces.2346 Cell Reports 23, 2342–2353, May 22, 2018To analyze migration of myosin IIa-deficient B cells in vivo,
we i.v. injected labeled CD23Cre+Myh9fl/fl and CD23Cre+
Myh9fl/wt B cells into C57BL/6J mice and found an in-
creased ratio of myosin IIa-deficient cells in the LNs after
Figure 4. Disturbed Migration and In Vivo
Trafficking of Myosin IIa-Deficient B Cells
(A) Velocity of CXCL13-activated CD23Cre+
Myh9wt/fl and CD23Cre+Myh9fl/fl B cells on an ICAM-
1-coated glass surface (n > 48 cells). ***p < 0.001
(Mann-Whitney U test).
(B) Directional migration through BSA, ICAM-1, and
anti-Igk-coated Transwells of CD23Cre+Myh9wt/fl
and CD23Cre+Myh9fl/fl B cells toward the indicated
chemokines. Data are normalized on Cxcl12-medi-
ated migration of CD23Cre+Myh9wt/fl B cells.
Mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001
(unpaired t test).
(C) Ratio of B cells from CD23Cre+Myh9wt/fl and
CD23Cre+Myh9fl/fl mice after i.v. injection into
C57BL/6J mice normalized to input ratio (n = 8
mice). Mean ± SD. LN, lymph node.
See also Figure S6.1, 4, and 16 hr (Figure 4C). This skewed ratio of B cells in
the LN was not due to facilitated homing of myosin IIa-defi-
cient cells caused by increased L-selectin (CD62L) expres-
sion, because we observed normal CD62L expression on
myosin IIa-deficient B cells (Figure S6C). To analyze whether
myosin IIa-deficient cells migrate normally within LNs, we
assessed the ratio of myosin IIa-deficient and myosin IIa-pro-
ficient B cells by immunofluorescence staining of cryopre-
served LNs 16 hr after transfer and found that the ratio of
myosin IIa-proficient and myosin IIa-deficient cells in B cell
follicles was similar to the ratio determined by flow cytometry
(Figure S6D).
Myosin IIa Is Required for Efficient Acquisition of
Antigen In Vivo
To investigate the role of myosin IIa in antigen acquisition
in vivo, CD23Cre+Myh9fl/wt and CD23Cre+Myh9fl/fl mice were
crossed with SWHEL mice. B cells of SWHEL mice express a
high-affinity anti-hen egg lysozyme (HEL) antibody as a BCR
on the cell surface (Phan et al., 2003). In the resulting mice,
approximately half of the B cells expressed the HEL-specific
BCR, as determined by binding of biotinylated HEL and
PE-labeled streptavidin (Figure S7A). A similar percentage of
cells could be stained with HEL3x, a modified version of
HEL with 10,000-fold lower affinity for the SWHEL BCR
(Paus et al., 2006), albeit with lower mean fluorescence
intensity (MFI). No difference was found in HEL binding
capacity between antigen-specific B cells of CD23Cre+
Myh9fl/wtSWHEL and CD23Cre
+Myh9fl/flSWHEL mice despite
lower surface IgM levels in the latter (Figure S7B), suggestingCelltotal surface BCR levels, which also
include immunoglobulin D (IgD), were
not significantly changed.
To target HEL antigen to FDCs in vivo, we
adapted a protocol to generate PE-labeled
HEL immune complexes in CD45.1mice by
intraperitoneal injection of anti-PE anti-
body, followed 1 day later by subcutane-
ous (s.c.) injection of HEL or HEL3x boundto PE-labeled streptavidin near the axillary and inguinal LNs
(Phan et al., 2007; Suzuki et al., 2009). Twenty-four hours after
generation of immune complexes, when most of the antigen is
presented on the surface of FDCs in LNs (Figure S7C), SWHEL
B cells were transferred. Fourteen hours after transfer, we iso-
lated B cells from axillary and inguinal LNs and could detect
PE-containing immune complexes on approximately 60% of
transferred B cells that express the SWHEL BCR. In contrast,
only 3% of donor B cells that do not express a HEL-specific
BCRwere positive for PE (Figure S7D), possibly because of cap-
ture of anti-PE-HEL-streptavidin-PE complexes via complement
receptor Cr2 (Phan et al., 2007). PE+ B cells had upregulated the
activation markers Cd69 and Cd86, demonstrating that the HEL
uptake is BCR mediated (Figure S7E). Omitting passive immuni-
zation with anti-PE antibody resulted in few PE-positive cells,
suggesting that the antigen has been taken up from immune
complex binding APCs.
To quantify HEL uptake from APCs in vivo in the absence
of myosin IIa, B cells from CD23Cre+Myh9fl/wtSWHEL and
CD23Cre+Myh9fl/flSWHEL were isolated, labeled, and transferred
concomitantly into HEL-immunized mice. After 14 hr, we found a
modest but significant reduction in HEL bound to myosin IIa-
deficient SWHEL B cells (Figure 5A). A similar reduction in antigen
uptake by myosin IIa-deficient SWHEL B cells was observed
when the lower-affinity HEL3x was used (Figure 5B). HEL-posi-
tive CD23Cre+Myh9fl/wtSWHEL and CD23Cre
+Myh9fl/flSWHEL
B cells equally upregulated Cd69 and Cd86 (Figure S7E),
demonstrating that access to antigen is similar. We conclude
that myosin IIa is a positive regulator of antigen acquisition of
membrane-bound antigen in vivo.Reports 23, 2342–2353, May 22, 2018 2347
Figure 5. Myosin IIa Is Required for Efficient
Acquisition of Low-Affinity Antigen In Vivo
(A) Flow cytometric analysis and quantification of
HEL-streptavidin-PE complex capture by B220+
cells from CD23Cre+Myh9fl/wtSWHEL or CD23Cre
+
Myh9fl/flSWHEL mice 14 hr after transfer into HEL-
streptavidin-PE-immunized CD45.1 mice. Plotted is
the MFI of PE+ cells, paired per mouse.
(B) Flow cytometric analysis and quantification of
HEL3x-streptavidin-PE complex capture by B220+
cells from CD23Cre+Myh9fl/wtSWHEL or CD23Cre
+
Myh9fl/flSWHEL mice 14 hr after transfer into HEL3x-
streptavidin-PE-immunized CD45.1 mice. Plotted is
the MFI of PE+ cells, paired per mouse.
Flow cytometry plots display data of a representative
experiment. *p < 0.05, **p < 0.01 (paired t test). See
also Figure S7.Myosin IIa-Deficient B Cells Have a Defect in
Cytokinesis
Past experiments with blebbistatin in HeLa and Cos-7 cells
demonstrated that class II myosins cooperate to separate
daughter cells during cytokinesis, the final step of the cell cycle
(Ma et al., 2012; Straight et al., 2003). Because myosin IIa is
the only class II myosin expressed in lymphocytes and both
the pro-B cell stage and the GC are sites of extensive B cell
proliferation, we hypothesized that myosin IIa-deficient B cells
may have a defect in cytokinesis. To investigate proliferation of
myosin IIa-deficient B cells, cells were labeled and cultured
in the presence of various stimuli. After 48 hr, up to 40%
of CD23Cre+Myh9fl/wt follicular B cells stimulated with lipo-
polysaccharide (LPS), CpG, or Cd40lg and interleukin-4 (IL-4)
had divided, as determined by dilution of dye (Figure 6A). In
contrast, less than 10% of CD23Cre+Myh9fl/fl B cells had prolif-
erated regardless of the stimulus. CpG-stimulated myosin
IIa-deficient B cells were markedly enlarged (Figure 6B), in
agreement with a defect in cytokinesis. Pro-B cells of Mb1Cre+
Myh9fl/fl mice were larger thanmyosin IIa-proficient counterparts
in Mb1Cre+Myh9fl/wt mice (Figure 6C), suggesting these cells
may have failed cytokinesis in vivo.
When stimulated with CpG for 48 hr in vitro, a higher propor-
tion of myosin IIa-deficient B cells were in G2 or M phase,
harboring 4N of DNA, as determined by propidium iodide incor-
poration, and indicating a block in a late phase of the cell cycle
(Figures 6D and 6E). Moreover, CpG stimulation of myosin IIa-
deficient B cells resulted in a large fraction of cells containing
more than 4N of DNA, suggesting these cells failed to complete
cytokinesis and entered the cell cycle again. Thus, myosin IIa is
essential for B cell proliferation, explaining the block of B cell
development and loss of GC cells in vivo.2348 Cell Reports 23, 2342–2353, May 22, 2018Myosin IIa Is Essential for Antibody
Responses
Collectively, the cytokinesis defect, the
reduced levels of MZ and GC B cells, and
the reduced capacity to acquire antigen
could result in disrupted antibody produc-
tion. CD23Cre+Myh9fl/fl mice had dimin-
ished levels of steady-state serum IgMand immunoglobulin G (IgG) 1, IgG2b, and IgG3 (Figure 7A). To
study the role ofmyosin IIa in antibody responses, we transferred
BM from CD23Cre+Myh9fl/wt and CD23Cre+Myh9fl/fl mice into
Rag1-KO mice. After reconstitution, mice were immunized with
the T-dependent antigen 4-hydroxy-3-nitrophenylacetyl-
chicken gamma globulin (NP-CGG), and NP-specific antibodies
in the serumwere analyzed after 7 and 10 days. NP-specific IgG1
antibodies were not detected in CD23Cre+Myh9fl/fl-reconsti-
tuted mice, whereas a clear induction of NP-specific IgG1
antibodies was found in CD23Cre+Myh9fl/wt-reconstituted mice
(Figure 7B). Some NP-specific IgM could be detected in immu-
nized CD23Cre+Myh9fl/fl-reconstituted mice, although at lower
levels than in immunized CD23Cre+Myh9fl/wt-reconstituted
mice. When immunized with the T-independent antigen NP-
Ficoll, CD23Cre+Myh9fl/fl-reconstituted mice did not generate
detectable levels of NP-specific IgG3 (Figure 7C). A small
induction of NP-specific IgM could be detected but was signifi-
cantly less than in CD23Cre+Myh9fl/wt-reconstituted mice. We
conclude that myosin IIa is essential for mounting efficient
B cell antibody responses.
DISCUSSION
Bcell antigen acquisition from the surface of APCs is increasingly
recognized as an important step in B cell responses (Cyster,
2010). Previous in vitro genetic and pharmacological perturba-
tions identified myosin IIa contractility as an important factor in
antigen extraction and delivery into MHC class II-containing pro-
cessing compartments (Natkanski et al., 2013; Vascotto et al.,
2007). Here, using mice in which myosin IIa was conditionally or
inducibly deleted from mature B cells, we demonstrate that
myosin IIa is important for antigen acquisition from FDCs in vivo.
Figure 6. Myosin IIa-Deficient B Cells Have a Defect in Cytokinesis
(A) Percentage of CD23Cre+Myh9wt/fl and CD23Cre+Myh9fl/fl B cells that have divided after 48 hr of cell culture in the presence of indicated stimuli.
(B) Light microscopy images of CD23Cre+Myh9wt/fl and CD23Cre+Myh9fl/fl B cells stimulated with CpG for 48 hr.
(C) Size of BM B220+CD19+CD2IgM pro-B cells of Mb1Cre+Myh9wt/fl and Mb1Cre+Myh9fl/fl mice.
(D) Flow cytometric analysis of propidium iodide incorporation of CD23Cre+Myh9wt/fl and CD23Cre+Myh9fl/fl B cells stimulated with CpG for 48 hr.
(E) Quantification of cells in G2/M phase and cells with more than 4N of DNA after 48 hr of CpG stimulation.
Means ± SD. **p < 0.01, ***p < 0.001 (unpaired t test).This is consistent with our discovery that FDCs have stiff mem-
branes compared to other APCs, requiring application of strong
forces by antigen-extracting B cells (Spillane and Tolar, 2017).
We have also found that GC B cells have increased force gener-
ation capability, supporting that strong forces are required for
antigen extraction in the GC (Nowosad et al., 2016). However,
the rapid and complete disappearance of myosin IIa-deficient
GC B cells, most likely due to a cytokinesis defect, prevented
us from analyzing these cells in this study.
The extraction of membrane-bound antigen was only reduced
by approximately 50% after genetic deletion of myosin IIa, in
contrast to the 80%–90% reported with blebbistatin inhibition
(Natkanski et al., 2013; Nowosad et al., 2016). This milder effect
of myosin IIa deletion on antigen uptake prevented us from
assessing the potential effects of cellular mechanics on antigen
affinitydiscrimination in thismodel. It is possible thatgeneticdele-
tion ofmyosin IIa canbe compensated by othermolecularmotors
or that blebbistatin has off-target effects that further diminish
force generationbyBcells. Differencesbetweengenetic inactiva-
tion of myosin IIa and inhibition by blebbistatin have also been
observedwhenstudyingcytokinesis (Maet al., 2012). Along these
lines, we found that myosin IIa was not required for processing
andpresentationof soluble antigens, as reportedpreviously (Vas-cotto et al., 2007). Possibly, alternative compensatory mecha-
nisms take over this process after long-term genetic deletion of
myosin IIa. This suggests caution is requiredwhen interpreting in-
hibitor or genetic studies in isolation.
When we analyzed antigen acquisition by myosin IIa-deficient
B cells from APCs in vivo, we found that it was only modestly
reduced, suggesting that substantial antigen extraction can be
achieved without specialized myosin IIa-dependent pulling ac-
tivity in the immune synapse. Again, deletion of myosin IIa may
have been compensated by other molecular motors. In addition,
the disturbed migration of myosin IIa-deficient B cells may facil-
itate antigen uptake in vivo due to prolonged interaction with the
APC. Further studies on the role of cellular motility in B cell anti-
gen acquisition should resolve this question.
Our analysis of myosin IIa-deficient B cells also shows that
myosin IIa is important for the development of MZ and B1b
B cells and negatively regulates the activation of follicular B cells.
A loss of MZ B cells, combined with an activated phenotype of
follicular B cells, has previously been reported in mice lacking
negative regulators of BCR signaling, such as Cd22 and Aiolos
(Cariappa et al., 2001; Nitschke et al., 1997; Sato et al., 1996),
and in transgenic mice expressing a self-reactive BCR (Cooke
et al., 1994; Goodnow et al., 1988) or overexpressing Cd19Cell Reports 23, 2342–2353, May 22, 2018 2349
Figure 7. Myosin IIa Is Essential for Antibody Responses
(A) Serum immunoglobulin levels of CD23Cre+Myh9fl/wt and CD23Cre+Myh9fl/fl mice.
(B) NP-specific immunoglobulin levels of CD23Cre+Myh9fl/wt and CD23Cre+Myh9fl/fl BM-reconstituted mice after immunization with the T-dependent antigen
NP-CGG (n = 10).
(C) NP-specific immunoglobulin levels of CD23Cre+Myh9fl/wt and CD23Cre+Myh9fl/fl BM-reconstituted mice after immunization with the T-independent antigen
NP-Ficoll (n = 5).
Dots represent individual mice analyzed in two experiments. Horizontal bars reflect mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 (unpaired t test).(Tedder et al., 1997). This suggests that myosin IIa is a negative
regulator of BCR signaling.
Sustained BCR signaling may render B cells anergic in vivo
(Cooke et al., 1994; Goodnow et al., 1988). Although myosin IIa-
deficient B cells responded normally to antigen stimulation, we
observed a reduced capacity to upregulate Cd86, a feature previ-
ously attributed to anergicBcells (Benschopet al., 2001;Rathmell
et al., 1998), suggesting myosin IIa-deficient B cells may have
become partly anergic. Anergic B cells are short lived (Santulli-
Marotto et al., 1998), which may explain the reduced numbers of
follicular B cells in competitive BM chimeras. Hyper-responsive-2350 Cell Reports 23, 2342–2353, May 22, 2018ness of follicular B cells has also been described in mice in which
other componentsof theBcell cytoskeletonorBCR internalization
or trafficking machinery were deleted, such asWas, Dbnl, or Cbl,
often resulting in a mild autoimmune phenotype (Becker-Herman
et al., 2011; Kitaura et al., 2007; Seeley-Fallen et al., 2014; Song
et al., 2013). However, follicular B cells in these mice did not
develop a hyperactivated surface phenotype, suggesting that
myosin IIamay regulate B cell activation by a distinctmechanism.
Possibly, myosin IIa may regulate BCR signaling under specific
conditions, such as signaling induced by antigen presented
on APCs or during a distinct developmental step. In support,
transgenic expressionof antigenonFDCs resulted in reduced IgM
and increased MHC class II on antigen-specific naive follicular
B cells (Yau et al., 2013), suggesting that BCR signaling induced
byFDC-presented ligands in the spleen could lead to an activated
phenotype similar to that observed in mice with B cell-specific
deletion of myosin IIa. However, the exact nature of the signaling
pathwayactivated in themyosin IIa-deficient B cells remains to be
identified, because we did not observe an obvious increase in ca-
nonical BCR signaling induced by either soluble or membrane-
bound antigens.
Analysis of adhesion in vitro showed that myosin IIa-deficient
B cells adhered normally to soluble or immobilized ICAM-1.
Moreover, when co-stimulated with both membrane-bound an-
tigen and immobilized ICAM-1, BCR signaling was similar in
myosin IIa-deficient and myosin IIa-proficient B cells (data not
shown), demonstrating that initial attachment to ICAM-1 is
normal. However, time-lapse imaging and Transwell experi-
ments demonstrated that B cells require myosin IIa for detach-
ment from adhesive substrates, similar to what has been
described for myosin IIa-deficient T cells (Jacobelli et al., 2010;
Morin et al., 2008). We speculate that this defect in detachment
from adhesive substrates may result in prolonged interaction
with antigen on APCs and thus in sustainedBCR signaling in vivo.
Lsc-deficient mice, which also have a defect in ICAM-1 detach-
ment, harbor reduced MZ B cell numbers and follicular B cells
with a hyperactivated phenotype (Girkontaite et al., 2001; Rubt-
sov et al., 2005), partly recapitulating the phenotype of mice with
myosin IIa-deleted B cells described here.
Although the loss of MZ B cells after myosin IIa deletion is
consistent with sustained BCR signaling, at least three other sig-
nals that are required for MZ B cell development could be poten-
tially involved in this phenotype (Pillai and Cariappa, 2009). First,
MZ B cell development needs Notch2 signaling. Interaction of
Notch2 with its ligand Dll1 initiates cleavage of Notch2 by
Adam10 (Gibb et al., 2010), an event that could rely on myosin
IIa-mediated Adam10 transport, force generation, or cell ten-
sion. However, we measured normal Adam10 surface transloca-
tion after BCR stimulation and normal upregulation of Notch
target genes in myosin IIa-deficient B cells, suggesting myosin
IIa does not influence Notch signaling. Second, MZ B cell devel-
opment depends on canonical nuclear factor kB (NF-kB)
signaling, most likely induced by Tnfsf13b (BAFF). However, ge-
netic disruption of canonical NF-kB signaling does not result in
upregulation of activation markers. Moreover, in vitro survival
in the presence of BAFF was normal in myosin IIa-deficient B
cells (data not shown), suggesting myosin IIa is also not required
for overall regulation of BAFF signaling. Finally, MZ B cell devel-
opment and maintenance require migration and subsequent
retention in the MZ (Lu and Cyster, 2002), which could depend
on myosin IIa. However, we found increased labeling of myosin
IIa-deficient MZ B cells after injection of anti-Cd19 antibody,
indicating that more, not fewer, myosin IIa-deficient MZ B cells
are localized in the MZ and red pulp. Possibly, a decrease in
myosin IIa-dependent cellular locomotion may result in less
shuttling of MZ B cells between the MZ and the follicle.
MZ B cells could also suffer from the observed cytokinesis
defect, although proliferation of MZ B cells during steady-state
conditions is generally very low and has, to our knowledge,only been reported when BM B cell development is blocked
(Hao and Rajewsky, 2001). It is conceivable that declining
numbers of MZ B cells at some point induce proliferation of re-
maining MZ B cells, thereby accelerating loss of MZ B cells
through the defect in proliferation. However, loss of myosin IIa-
deficient MZ B cells was also observed in the presence of
wild-typeMZB cells in competitive BM chimeras, demonstrating
that the initial loss of MZ B cells is cell intrinsic.
Overall, our data show that myosin IIa is required for efficient
antibody responses, which is likely a result of the combined ef-
fects on antigen acquisition and proliferation. It is probable that
because of these effects,myosin IIa-deficient Bcellswere unable
to contribute to autoimmune reactions despite their activated
phenotype, in contrast to the reported autoimmune syndromes
in other mice with disturbed BCR internalization and trafficking
(Becker-Herman et al., 2011; Kitaura et al., 2007; Song et al.,
2013). Myosin IIa has been identified as a tumor suppressor by
cytokinesis regulation or by post-transcriptional regulation of
p53 (Conti et al., 2015; Schramek et al., 2014). We found several
p53 target genes downregulated in myosin IIa-deficient follicular
B cells, suggesting p53 function may also be deregulated in
myosin IIa-deficient follicular B cells. However, whereas p53
null mice develop spontaneous lymphomas (Harvey et al.,
1995), it is likely that transformation ofmyosin IIa-deficient B cells
is again limited by the proliferation defect described in this paper.
Our data thus establish a critical role of myosin contractility in
multiple aspects of B cell biology and should open new avenues
to study the role of the cytoskeleton and B cell intrinsic force gen-
eration in antibody responses.
EXPERIMENTAL PROCEDURES
Mice
Myh9fl/fl (Myh9tm5Rsad) mice were crossed with Mb1Cre (Cd79atm1(cre)Reth),
CD23Cre (Tg(Fcer2a-cre)5Mbu), and R26ERT2Cre (Gt(ROSA)
26Sortm1(cre/ERT2)Thl) mice as described previously (de Luca et al., 2005; Ho-
beika et al., 2006; Jacobelli et al., 2010; Kwon et al., 2008). CD23CreMyh9fl/fl
mice were crossed with SWHEL (Igh
tm1Rbr-Tg(IgkHyHEL10)1Rbr) mice (Phan
et al., 2003). 6–12 week old male and female mice were used for ex vivo anal-
ysis of cell populations. For in vitro experiments, cells isolated from 6–20 week
old mice were used.
To generate BM transfer or chimeramice,Rag1-deficient mice (Rag1tm1Mom)
were irradiated with 5 Gy and reconstituted with BM cells by i.v. injection.
R26ERT2Cre+Myh9 mice received 2 mg/day of tamoxifen (Sigma) suspended
in corn oil by intraperitoneal injection for 5 days. When indicated, BM was
mixed with 80% muMT (Ighmtm1Cgn) or CD45.1 (B6.SJL-Ptprca/Nimr). Mice
were bred and kept in accordance with guidelines set by the UK Home Office
and the Francis Crick Institute Ethical Review Panel.
Large-Scale Imaging
Generation of PMS and the large-scale imaging approach have been
described previously (Natkanski et al., 2013; Nowosad et al., 2016). A brief
description is provided in Supplemental Experimental Procedures.
Antigen Acquisition
To study in vivo antigen acquisition, we adapted a protocol to generate HEL-
containing immune complexes as described previously (Phan et al., 2007).
CD45.1 mice were passively immunized with a polyclonal anti-PE antibody
(Rockland Immunochemicals). The next day, 10 mg of biotinylated HEL or
HEL3x protein, produced in house as described (Paus et al., 2006), was com-
plexed to PE-labeled streptavidin (BioLegend) and injected s.c. near the
inguinal and axillary LNs under isoflurane anesthesia. The following day,Cell Reports 23, 2342–2353, May 22, 2018 2351
CD23Cre+Myh9fl/wtSWHEL and CD23Cre
+Myh9fl/flSWHEL B cells were isolated,
fluorescently labeled, mixed, and transferred to immunized recipient mice
by i.v. injection. After 14 hr, inguinal and axillary LNs were harvested and
analyzed by flow cytometry.
In vitro internalization and presentation of soluble antigen are described in
Supplemental Experimental Procedures.
Adhesion and Migration
To investigate in vivo homing andmigration, B cells were labeled with 5-chloro-
methylfluorescein diacetate (CMFDA) and CellTrace Far Red (CTFR) andmixed
in a 1:1 ratio, and 203 106 cells were i.v. injected into C57BL/6J recipient mice.
At indicated times, LNs were collected and the ratio of donor cells was deter-
mined by flow cytometry or immunofluorescence microscopy of cryosections.
To determine localization of myosin IIa-deficient MZ B cells, R26ERT2Cre+
Myh9 muMT BM chimeras were treated with tamoxifen as described earlier.
14 days after the first tamoxifen injection, mice received 1 mg anti-Cd19-PE
antibody by i.v. injection. Mice were culled 5 min later, splenocytes were har-
vested on ice, and cells were analyzed by flow cytometry. In vitro migration
and adhesion experiments are described in Supplemental Experimental
Procedures.
Flow Cytometry, Signaling, Activation, and Proliferation
B cell populations, signaling, activation, proliferation, and gene expression
were analyzed using standard techniques described in Supplemental Experi-
mental Procedures.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 7 software. For
each experiment, the statistical test used, the sample size, and the statistical
significance are included in the figure legend.
DATA AND SOFTWARE AVAILABILITY
The accession number for the data from transcriptomic analysis reported in
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